

# INPLASY PROTOCOL

To cite: Chen et al. Correlation of neutrophil to lymphocyte ratio and prognosis in patients with stage II-IV esophageal squamous cell carcinoma: a systematic review and meta-analysis. Inplasy protocol 202250152. doi: 10.37766/inplasy2022.5.0152

Received: 27 May 2022

Published: 27 May 2022

**Corresponding author:**  
Zhe Chen

qq1278017702@163.com

**Author Affiliation:**  
Dushu Lake Hospital,  
Soochow University.

**Support:** Jiangsu  
NSF:BK20191174.

**Review Stage at time of this submission:** Completed but not published.

**Conflicts of interest:**  
None declared.

## Correlation of neutrophil to lymphocyte ratio and prognosis in patients with stage II-IV esophageal squamous cell carcinoma: a systematic review and meta-analysis

Chen, Z<sup>1</sup>; Wang, W<sup>2</sup>; Ma, H<sup>3</sup>; Wang, N<sup>4</sup>; Li, J<sup>5</sup>.

**Review question / Objective:** This study aimed to summarize the prognostic correlation of NLR at baseline in patients with stage II-IV esophageal squamous cell carcinoma. **P:** Patients with stage II-IV esophageal squamous cell carcinoma; **I:** High level of NLR at baseline; **C:** Low level of NLR at baseline; **O:** Survival outcome; **S:** RCT studies and retrospective studies.

**Condition being studied:** The incidence of esophageal cancer in eastern countries increases yearly, and most patients with esophageal cancer are diagnosed at a non-early stage.

**Eligibility criteria:** Inclusion criteria: 1. The study population included patients with squamous esophageal cancer; 2. There is a definite NLR cutoff value; 3. The number of people included in the study should not be too small; 4. RCT studies or retrospective studies. Exclusion criteria: 1. Survival outcome indicators related to prognosis cannot be extracted; 2. Non-English articles; 3. Articles that repeat studies on the same patients.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 27 May 2022 and was last updated on 27 May 2022 (registration number INPLASY202250152).

### INTRODUCTION

**Review question / Objective:** This study aimed to summarize the prognostic correlation of NLR at baseline in patients with stage II-IV esophageal squamous cell carcinoma. **P:** Patients with stage II-IV

esophageal squamous cell carcinoma; **I:** High level of NLR at baseline; **C:** Low level of NLR at baseline; **O:** Survival outcome; **S:** RCT studies and retrospective studies.

**Condition being studied:** The incidence of esophageal cancer in eastern countries

---

increases yearly, and most patients with esophageal cancer are diagnosed at a non-early stage.

## METHODS

**Participant or population:** Stage II-IV esophageal squamous cell carcinoma.

**Intervention:** High level of NLR at baseline.

**Comparator:** Low level of NLR at baseline.

**Study designs to be included:** RCT studies and retrospective studies.

**Eligibility criteria:** Inclusion criteria: 1. The study population included patients with squamous esophageal cancer; 2. There is a definite NLR cutoff value; 3. The number of people included in the study should not be too small; 4. RCT studies or retrospective studies. Exclusion criteria: 1. Survival outcome indicators related to prognosis cannot be extracted; 2. Non-English articles; 3. Articles that repeat studies on the same patients.

**Information sources:** Pubmed, Embase, The Cochrane Library, Web of science.

**Main outcome(s):** Overall survival and other related prognostic indicators.

**Quality assessment / Risk of bias analysis:** Retrospective study: Newcastle-Ottawa Scale (NOS); RCT study: Modified Jadad scale.

**Strategy of data synthesis:** Different analysis types are selected according to whether there is a high degree of heterogeneity in the collected effect size. The random effect model is used for high heterogeneity, and the fixed effect model is used for low heterogeneity.

**Subgroup analysis:** Subgroup studies were performed according to the number of patients included in the literature, treatment modality, NLR cutoff value, type of survival analysis, and clinical stage.

**Sensitivity analysis:** Observe the change in the combined effect size after removing any one effect size.

**Country(ies) involved:** China.

**Keywords:** esophageal cancer, meta-analysis, neutrophil-to-lymphocyte ratio, prognosis.

### Contributions of each author:

Author 1 - Zhe Chen.

Author 2 - Weichao Wang.

Author 3 - Haitao Ma.

Author 4 - Nan Wang.

Author 5 - Jiayi Li.